Dr. Reddy's Laboratories Limited — PPTs, 12-05-2026: Investor Presentation

Dr. Reddy's reported its Q4 and full-year results, showing a diversified business model. Q4 revenues reached ₹7,516 Cr, up 12% year-over-year, with profit after tax (PAT) soaring 86% to ₹220 Cr. For the full year, revenues grew 3% to ₹33,593 Cr, and PAT jumped 24% to ₹4,285 Cr. Growth was broad-based across India and Emerging Markets, while North America saw some moderation.

The company is strategically focused on strengthening its core businesses and building future growth drivers like peptides, biosimilars, and consumer health. Key pipeline products, including Semaglutide and Abatacept, are being advanced.

Recent achievements include becoming the first company to secure Canadian approval for generic semaglutide injection, followed by its Day 1 launch in India as 'Obeda®'. The US health authority also accepted its abatacept biosimilar for review. Dr. Reddy's further expanded into Hormone Replacement Therapy with a key acquisition and completed integration of 95% of its acquired NRT business.

Management emphasized continuous efforts to enhance capabilities, drive operational efficiencies, and maintain a focus on quality and sustainability, leveraging both organic growth and M&A opportunities.